Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain
Stock Information for Creative Medical Technology Holdings Inc.
Loading
Please wait while we load your information from QuoteMedia.